Asset profile
Divalproex sodium (Depakote)
Small molecule
Evidence outlook
Approved: Epilepsy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also in development:Migraine · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 108 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Divalproex Sodium (Depakote): this drug | Approved | Small molecule | GABAergic neurotransmission | ||
| Divalproex Sodium (Depakote ER) | Approved | — | GABAergic neurotransmission | ||
| Valproate | Approved | Small molecule | GABAergic neurotransmission | ||
| Almotriptan (Axert) | Approved | Small molecule | — | ||
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | — | ||
| Atogepant (Qulipta) | Approved | Small molecule | — | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| Carbamazepine | Approved | Small molecule | Sodium channels | ||
| Celecoxib (Elyxyb) | Approved | Small molecule | — | ||
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.